

Curriculum Vitae

Andreas Linkermann



Univ.-Prof. Dr. med. Andreas Linkermann, FASN

Medical Clinic III, Division of Nephrology

Universitätsklinikum Carl Gustav Carus Dresden

Fetscherstr. 74

01307 Dresden, Germany

Phone: +49-(0)351-458-7631

Mobile phone: +49-(0)177-3226147

Assistant phone (Ms Dollfus / Ms Kaul): +49-(0)351-458-3075

Fax: +49-(0)351-458-5333

Email: andreas.linkermann@ukdd.de

Curriculum Vitae

Professional Education

| | |
|-------------------|--|
| - 1996 | Gymnasium - Abitur |
| 08/1996 – 07/1997 | Civil service, Neurosurgery Unit, Hospital Minden, Germany |
| 08/1997 – 07/1999 | Apprenticeship - Banker (Deutsche Bank AG) |
| 10/1999 – 05/2006 | Christian-Albrechts-University, Kiel – Medical school |
| 07/2006 – 09/2016 | Department of Internal Medicine and Nephrology, UK-SH, Campus Kiel |
| 07/2008 | MD thesis from Institute for Immunology, CAU Kiel (Summa cum laude) |
| 06/2012 | Board exam in Internal Medicine – Internist („Facharzt für Innere Medizin“) |
| 09/2013 | Board exam Nephrology – Nephrologist („Zusatzbezeichnung Nephrologie“) |
| since 12/2013 | “Oberarzt” (Senior consultant nephrologist) |
| 12/2014 | “Habilitation” and “Venia legend” at the CAU (full faculty member) |
| 10/2016 – present | Universitätsklinikum Carl Gustav Carus Dresden |
| 10/2016 – present | Deputy director – Division of Nephrology |
| 12/2018 – present | W2 Professorship for Clinical Cell Death Research |
| 12/2018 – present | Heisenberg-Professorship |
| 02/2020 – present | Faculty member of IRTG 2251 (international research training group with King’s College London) |

Awards

| | |
|---------|--|
| 11/2001 | Member of the „Studienstiftung des Deutschen Volkes“ |
| 06/2009 | Faculty award „Fakultätspreis der medizinischen Fakultät der CAU Kiel“ |
| 07/2009 | Award of the Dean of the Christian-Albrechts University „Dekanatspreis der CAU Kiel“ |
| 12/2009 | Beigel-Research Award „Beigel’scher Preis“ |
| 09/2011 | Research award of the German Society for Nephrology (DGfN) |
| 04/2013 | ASN Kidney week - faculty member (annually until today) |
| 10/2013 | Best Poster award at the German Society of Nephrology (DGfN) |
| 10/2013 | Excellence Cluster “Inflammation at Interfaces” - full member |
| 02/2014 | Young Innovator Award - American Society of Transplantation (AST) |
| 07/2014 | “Carl-Ludwig-Preis” of the German Society of Nephrology (DGfN) |
| 11/2014 | STS-Science-Award (Signal Transduction Society) |
| 06/2015 | Fellow of the American Society of Nephrology (FASN) |
| 07/2015 | “Franz-Volhard-Preis” of the German Society of Nephrology (DGfN)* |
| 10/2015 | “GSK Award” at Cold Spring Harbor Asia meeting on Cell Death |
| 03/2016 | Honorary Member of the European Academy of Tumor Immunology (EATI) |
| 10/2016 | “Rudolf Pichlmayr Preis” - German Society of Transplantation (DTG)* |
| 07/2018 | ERC Starting Grant rate “A” – 2018 reserve list candidate |

*A. Linkermann is the only person who received both the two single most prestigious European honors in Transplantation (Rudolf-Pichlmayr-Price) and Nephrology (Franz-Volhard-Price)

Dresden, in June 2020



Univ.-Prof. Dr. med. Andreas Linkermann, FASN

List of Publications

Univ.-Prof. Dr. med. Andreas Linkermann

06/2020

Overall impact factors: 1.001,44

Average impact factor: 10,43

(96 publications, incl. primary publications, reviews, editorials and case reports.

In 51 of 96 publications, A. Linkermann is first or last author (53,1%)

Primary Publications:

1. Južnić L., Peuker K., Strigli A., Brosch M., Herrmann A., Häsler R., Koch M., Matthiesen L., Zeissig Y., Löscher B.S., Nuber A., Schotta G., Neumeister V., Chavakis T., Kurth T., Lesche M., Dahl A., von Mässenhausen A., **Linkermann A.**, Schreiber S., Aden K., Rosenstiel P.C., Franke A., Hampe J. and Zeissig S. (2020) SETDB1 is required for intestinal epithelial differentiation and the prevention of intestinal inflammation *Gut - EPub ahead of print*
2. Fang X., Cai Z., Wang H., Han D., Cheng Q., Zhang P., Gao F., Yu Y., Song Z., Wu Q., An P., Huang S., Pan J., Chen H.Z., Chen J., **Linkermann A.**, Min J. and Wang F. (2020) Loss of Cardiac Ferritin H Facilitates Cardiomyopathy via Slc7a11-Mediated Ferroptosis *Circulation research - EPub ahead of print*
3. Belavgeni, A. *, Bornstein, S.R. *, von Mässenhausen, A., Tonnus, W., Stumpf, J., Meyer, C., Othmar, E., Latk, M., Kanczkowski, W., Kroiss, M., Hantel, C., Hugo, C., Fassnacht, M., Ziegler, C.G., Schally, A.V., Krone, N.P. and **Linkermann, A.** (2019) Exquisite Sensitivity of Adrenocortical Carcinomas to Induction of Ferroptosis *Proceedings of the National Academy of Science (PNAS)* Oct 29;116(44):22269-22274 - *shared first authors
4. Mulay, S.R., Honarpisheh, M.M., Foresto-Neto, O., Shi, C., Desai, J., Zhao, Z.B., Marschner, J.A., Popper, B., Buhl, E.M., Boor, P., **Linkermann, A.**, Liapis, H., Bilyy, R., Herrmann, M., Romagnani, P., Belevich, I., Jokitalo, E., Becker, J.U., Anders, H.J. (2019) Mitochondria permeability transition versus necroptosis in oxalate-induced acute kidney injury *Journal of the American Society of Nephrology (JASN)* Oct;30(10):1857-1869.
5. Li, W., Feng, G., Gauthier, J.M., Lokshina, I., Higashikubo, R., Evans, S., Liu, X., Hassan, A., Tanaka, S., Cicka, M., Hsiao, H.-M., Ruiz-Perez, D., Bredemeyer, A., Gross R.W., Mann, D.L., Tyurina Y.Y., Gelman, A.E., Kagan, V.E., **Linkermann, A.**, Lavine, K.J., and Kreisler, D. (2019) Ferroptotic cell death and TLR4/Trif signaling initiate neutrophil recruitment after heart transplantation *The Journal of Clinical Investigation (JCI)* – Feb 26;130.
6. Fang, X., Wang, H., Han, D., Xie, E., Yang, X., Wie, J., Gu, S., Gao, F., Zhu, N., Yin, X., Cheng, Q., Zhang, P., Dai, W., Chen, J., Yang, F., Yang, H.-T., **Linkermann, A.***, Gu, W.* , Min J. and Wang, F.* (2019) Ferroptosis as a novel target for protection against cardiomyopathy *Proceedings of the National Academy of Science (PNAS)* – Feb 12;116(7):2672-2680. *shared corresponding authors
7. Aljabri, A., Vijayan, V., Stankov, M., Nikolin, C., Figueiredo, C., Blasczyk, R., Becker, J.U., **Linkermann, A.**, Immenschuh, S. (2019) HLA class II antibodies induce necrotic cell death in human endothelial cells via a lysosomal membrane permeabilization-mediated pathway *Cell Death and Disease* - Mar 8;10(3):235
8. Lafont, E., Draber P., Rieser E., Reichert M., Kupka S., de Miguel D., Draberova H., von Mässenhausen A., Bhamra A., Henderson S., Wojdyla K., Chalk A., Surinova S., **Linkermann A.** and Walczak, H. (2018) M1-ubiquitin- and NEMO-recruited TBK1/IKKε prevent TNF-induced cell death by RIPK1 phosphorylation *Nature Cell Biology (NCB)* – Dec;20(12):1389-1399

9. Stoppe, C., Averdunk, L., Goetzenich, A., Soppert, J., Marlier, A., Kraemer, S., Vieten, J., Coburn, M., Kowark, A., Kim, B-S., Marx, G., Rex, S., Ochi, A., Leng, L., Moeckel, G., **Linkermann, A.**, El Bounkari, E., Zarbock, A., Bernhagen, J., Djudjaj, S., Bucala, R. and Boor, P. (2018) The protective role of macrophage migration inhibitory factor in acute kidney injury after cardiac surgery *Science translational medicine (STM)* - 16 May 18; 10, eaan4886
10. Bruni, A., Pepper, A.R., Pawlick, R.L., Gala-Lopez, B., Gamble A.F., Kin, T., Seeberger, K., Korbitt, G.S., Bornstein, S.R., **Linkermann, A.***, Shapiro A.M*. (2018) Ferroptosis-inducing agents compromise in vitro human islet viability and function *Cell death and disease (CDDis)* – 2018-9:595 *shared senior authors
11. Martin-Sanchez, D., Fontecha-Barriuso, M., Carrasco, S., Sanchez-Niño, M., von Mässenhausen, A., **Linkermann, A.**, Cannata-Ortiz, P., Ruiz-Ortega, M., Egido, J., Ortiz, A. and Sanz., A.B. (2018) TWEAK and RIPK1 mediate a second wave of cell death during AKI. *Proceedings of the National Academy of Science (PNAS)* – Apr 17;115(16):4182-4187
12. Gaschler M.M., Hu F., Feng H., **Linkermann A.**, Min W. and Stockwell B.R. (2018) Determination of the subcellular localization and mechanism of action of ferrostatins in suppressing ferroptosis. *ACS Chem Biol.* – Apr 20;13(4):1013-1020
13. Fuchslocher Chico J., Falk-Paulsen, M., Luzius, A., Saggau, C., Ruder, B., Bolik, J., Schmidt-Arras, D., **Linkermann, A.**, Becker, C., Rosenstiel, P., Rose-John, S., and Adam, D. (2018) The enhanced susceptibility of ADAM-17 hypomorphic mice to DSS-induced colitis is not ameliorated by loss of RIPK3, revealing an unexpected function of ADAM-17 in necroptosis *Oncotarget* - Feb 5;9(16):12941-12958
14. von Mässenhausen, A.* , Tonnus, W.* , Himmerkus, N., Parmentier, S., Saleh, D., Rodriguez, D., Ousingsawat, J., Ang R.L., Weinberg, J.M., Sanz, A.B., Ortiz, A., Zierleyn, A., Becker, J.U., Baratte, J., Desban, N., Bach, S., Schiessl, I.M., Nogusa, S., Balachandran, S., Anders, H.J., Ting, A.T., Bleich, M., Degtrev, A., Kunzelmann, K., Bornstein, S.R., Green, D.R., Hugo, C., and **Linkermann, A.** (2018) Phenytoin inhibits necroptosis *Cell Death and Disease* Mar 2;9(3):359.
15. Schreiber A., Rousselle A., Becker J.U., von Mässenhausen A., **Linkermann A.** and Ketritz R. (2017) Necroptosis controls NETs generation and mediates complement activation, endothelial damage and autoimmune vasculitis *Proceedings of the National Academy of Science (PNAS)* Nov 7;114(45):E9618-E9625
16. Martens S., Takahashi N., Goossens V., Hofmans S., Van der Veken P., Joossens J., Augustyns K., Jeong M., Lee E.W., Song J, Tonnus W., Feldmann F., Fulda S. , Bräsen J.H. , **Linkermann A.** and Vandenabeele P. (2017) Sorafenib tosylate inhibits directly necrosome complex formation and protects in mouse models of inflammation and tissue injury *Cell death and disease* – Jun 29;8(6):e2904
17. Gong Y.-N., Guy C., Olauson H., Becker J.U., Yang M., Fitzgerald P., **Linkermann A.*** and Green D.R.* (2017): ESCRT-III acts downstream of MLKL to regulate necroptotic cell death and its consequences. *Cell* Apr 6;169(2):286-300, *Corresponding authors
18. Greve A.S. *, Skals M. *, Fagerberg S.K., Tonnus W., Ellermann-Eriksen S., Evans R.J., **Linkermann A.*** and Praetorius H.E.* (2017) P2X1, P2X4 and P2X7 receptor knock out mice expose differential outcome of sepsis induced by β -haemolysin producing Escherichia coli. *Frontiers in Cellular and Infection Biology* 2017 Apr 6;7:113. *Corresponding authors
19. Geismann C, Grohmann F, Dreher A, Häsler R, Rosenstiel P, Legler K, Hauser C, Egberts JH, Sipos B, Schreiber S, **Linkermann A**, Hassan Z, Schneider G, Schäfer H, Arlt A. (2017) Role of CCL20 mediated immune cell recruitment in NF- κ B mediated TRAIL resistance of pancreatic cancer. *Biochim Biophys Acta – Molecular Cell Research.* 2017 May;1864(5):782-796.
20. Ousingsawat J, Cabrita I, Wanitchakool P, Sirianant L, Krautwald S, **Linkermann A**, Schreiber R, Kunzelmann K (2017) Ca²⁺ signals, cell membrane disintegration, and activation of TMEM16F during necroptosis. *Cellular and Molecular Life Sciences (CMLS)* Jan;74(1):173-181
21. Martin-Sanchez D, Ruiz-Andres O, Poveda J, Carrasco J, Cannata-Ortiz P, Sanchez-Nino MD, Ortega MR, Egido M, **Linkermann A**, Ortiz A and Sanz AB (2017) Ferroptosis, but not necroptosis, plays an important role in nephrotoxic folic acid-induced acute kidney injury *Journal of the American Society of Nephrology (JASN)* Jan;28(1):218-229.

22. Günther C., He G., Kremer A., Murphy J., Petrie E., Amann K., Vandenabeele P., **Linkermann A.**, Poremba C., Schleicher U., Dewitz C., Krautwald S., Neurath M.F., Becker C. and Wirtz S. (2016) MLKL mediates programmed hepatocellular necrosis independent of RIPK3 during hepatitis. *The Journal of Clinical Investigation (JCI)* Nov 1;126(11):4346-4360
23. Gautheron J., Vucur M., Schneider A.T., Severi I., Roderburg C., Roy S., Bartneck M., Schrammen P., Berriel Diaz M., Ehling J., Gremse F., Heymann F., Koppe C., Lammers T., Kiessling F., Van Best N., Pabst O., Courtois G., **Linkermann A.**, Krautwald S., Neumann U., Tacke F., Trautwein C., Green D.R., Longrich T., Frey N., Lüdde M., Blüher M., Herzig S., Heikenwalder M. and Lüdde, T (2016) The necroptosis-inducing kinase RIPK3 dampens adipose tissue inflammation and glucose intolerance *Nature Communications* 21;7:11869
24. Martinez J., Cunha L., Park S., Yang M., Lu Q., Orchard R., Li Q.-Z., Yan M., Janke M., Guy C., **Linkermann A.**, Virgin H. and Green D.R. (2016) LC3-associated phagocytosis links clearance of dying cells to auto-inflammation and lupus-like disease in mice *Nature* May 5;533(7601):115-9.
25. Corcelle-Termeau, E., Vindeløv S.D., Hämälistö S., Mograbi B., Keldsbo A., Bräsen J.H., Favaro E., Adam D., Szyniarowski P., Hofman P., Krautwald S., Farkas T., Petersen N.H.T., Rohde M., **Linkermann A.**, Jäättelä M. (2016) Excess sphingomyelin disturbs ATG9A trafficking and autophagosome closure *Autophagy* May 3;12(5):833-49
26. Mulay S.R., Jyaysi D., Kumar V.R. Eberhard J.N., Thomasova D., Romoli S., Grigorescu M., Kulkarni O.P., Popper B., Vielhauer V., Zuchtriegel G., Reichel C., Bräsen J.H., Romagnani P., Bilyy R., Munoz L.E., Herrmann M., Liapis H., Krautwald S., **Linkermann A.** and Anders H.J. (2016) Cytotoxicity of crystals involves RIPK3-MLKL-mediated necroptosis in kidney stone disease *Nature Communications* Jan 28;7:10274
27. Desai J, Vr S.K., Mulay S.R., Konrad L., Romoli S., Schauer C., Herrmann M., Bilyy R., Müller S., Popper B., Nakazawa D., Weidenbusch M., Thomasova D., Krautwald S., **Linkermann A.**, Anders H.J. (2015) Neutrophil extracellular trap formation can involve RIPK1-RIPK3-MLKL signalling *Eur J Immunol.* (2016) Jan;46(1):223-9
28. Fauster A., Rebsamen M., Huber K., Bigenzahn J., Stukalov A., Lardeau C.-H., Scorzoni S., Bruckner M., Gridling M., Parapatics M., Colinge J., Bennett K., Kubicek S., Krautwald S., **Linkermann A.** and Superti-Furga G. (2015) A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis. *Cell Death and Disease*, May 21;6:e1767.
29. Ising C., Koehler S., Brähler S., Merkwirth C., Höhne M., Baris O.R., Hagmann H., Kann M., Fabretti F., Dafinger C., Bloch W., Schermer B., **Linkermann A.**, Brüning J.C., Kurschat C.E., Müller R.U., Wiesner R.J., Langer T., Benzing T., Brinkkoetter P.T. (2015) Inhibition of insulin/IGF-1 receptor signaling protects from mitochondria-mediated kidney failure. *EMBO Molecular Medicine*, Feb 2;7(3):275-87.
30. **Linkermann A.**, Skouta R, Himmerkus N, Mulay SR, Dewitz C, De Zen F, Prokai A, Zuchtriegel G, Krombach F, Welz PS, Weinlich R, Vanden Berghe T, Vandenabeele P, Pasparakis M, Bleich M, Weinberg JM, Reichel CA, Bräsen JH, Kundendorf U, Anders HJ, Stockwell BR, Green DR, Krautwald S. (2014) Synchronized renal tubular cell death involves ferroptosis. *Proceedings of the National Academy of Science (PNAS)* 25;111(47):16836-41
31. Luedde M, Lutz M, Carter N, Sosna J, Jacoby C, Vucur M, Gautheron J, Roderburg C, Borg N, Reisinger F, Hippe HJ, **Linkermann A.**, Wolf MJ, Rose-John S, Lüllmann-Rauch R, Adam D, Flögel U, Heikenwalder M, Luedde T, Frey N. (2014) RIP3, a kinase promoting necroptotic cell death, mediates adverse remodelling after myocardial infarction. *Cardiovascular Research* Jul 15;103(2):206-16
32. Skouta, R., Dixon, S.J., Wang, J., Dunn, D.E., Orman, M., Rosenberg, P.A., Lo, D.C., Weinberg, J.M., **Linkermann, A.** and Stockwell, B.R. (2014) Ferrostatins selectively inhibit lipid peroxidation in diverse disease models involving ferroptotic cell death. *Journal of the American Chemical Society (JACS)*, 26;136(12):4551-6.
33. Sosna, J., Voigt, S., Mathieu, S., Lange, A., Thon, L., Davarnia, P., Herdegen, T., **Linkermann, A.**, Rittger, A., Chan, F.K.M., Kabelitz, D., Schütze, S., Adam, D. (2014) TNF-induced necroptosis and PARP-1-mediated necrosis represent distinct and independent routes to programmed necrotic cell death. *Cellular and Molecular Life Sciences (CMLS)*, 71(2):331-48.

34. Tait S.W.G., Oberst A., Quarato, G., Milasta, S., Haller, M., Wang, R., Yatim, N., Albert, M., Krautwald, S., **Linkermann, A.** and Green D.R. (2013): Widespread depletion of mitochondria does not compromise RIPK3-mediated necroptosis. *Cell Reports* 27;5(4):878-85.
35. Lau, A., Wang, S., Jiang, J., Haig, A., Pavlosky, A., **Linkermann, A.**, Zhang, Z.-X., Jevnikar, A.M. (2013). RIPK3 mediated necroptosis promotes donor kidney inflammatory injury and reduces allograft survival. *American Journal of Transplantation* 13(11):2805-18.
36. **Linkermann, A.**, Bräsen J.H., Darding, M., Jin, M.K., Sanz, A.B., Heller, J.-O., De Zen, F., Weinlich, R., Ortiz, A., Walczak, H., Weinberg, J.M., Green, D.R., Kunzendorf, U., Krautwald, S. (2013). Two Independent Pathways of Regulated Necrosis Mediate Ischemia-Reperfusion Injury. *Proceedings of the National Academy of Science (PNAS)* 16;110(29):12024-9.
37. **Linkermann, A.**, Heller, J.-O., Prokai, A., Weinberg, J.M., De Zen, F., Himmerkus, N., Szabo, A.J., Bräsen, J.H., Kunzendorf, U., Krautwald, S. (2013). Osmotic Nephrosis and Contrast-Induced Acute Kidney Injury are prevented by the RIP1-kinase Inhibitor Necrostatin-1 in Mice. *Journal of the American Society of Nephrology (JASN)* Nov 24(10):1545-57.
38. **Linkermann, A.**, Bräsen, J.H., De Zen, F., Weinlich, R., Schwendener, R.A., Green, D.R., Kunzendorf, U., Krautwald, S. (2012). Dichotomy between RIP1- and RIP3-mediated Necroptosis in Tumor Necrosis Factor α -induced Shock. *Molecular Medicine* May 9;18:577-86.
39. **Linkermann, A.**, Bräsen, J.H., Himmerkus, N., Liu, S., Huber, T.B., Kunzendorf, U., Krautwald, S. (2011). RIP1-mediated necroptosis essentially contributes to renal ischemia/reperfusion injury. *Kidney International* 81, 751-761.
40. **Linkermann, A.**, Himmerkus, N., Rölver, L., Bleich, M., Bräsen, J.H., Kunzendorf, U., Krautwald, S. (2011). Blocking FasL in acute lethal Cisplatin induced renal failure prolongs survival in mice via two different mechanisms. *Kidney International* 79, 169-178.
41. Krautwald, S., Ziegler, E., Rölver, L., **Linkermann, A.**, Kayser, K., Mortimer-Klingebiel, S., Kunzendorf, U. (2010): Effective blockage of both the extrinsic and intrinsic pathways of apoptosis in mice by TAT-crmA. *Journal of Biological Chemistry*, Jun 25;285(26):19997-20005.
42. Lettau M., Pieper J., Gerneth A., Lengel-Janßen B., Voss M., **Linkermann A.**, Schmidt H., Gelhaus C., Leippe M., Kabelitz D., Janssen O. (2010): The adapter protein Nck: Role of individual SH3 and SH2 binding modules for protein interactions in T lymphocytes. *Protein Science*, Apr;19(4):658-69.
43. **Linkermann, A.**, Gelhaus, C., Lettau, M., Qian, J., Kabelitz, D., Janssen, O. (2009): Identification of interaction partners for individual SH3 domains of Fas ligand associated members of the PCH protein family in T lymphocytes, *BBA-Proteins and Proteomics*, 1794; 168-176.
44. Lettau, M., Qian, J., **Linkermann, A.**, Larose, L., Kabelitz, D., Janssen O (2006). The adaptor protein Nck interacts with Fas Ligand: Guiding the death factor to activation clusters and the immunological synapse. *Proceedings of the National Academy of Science (PNAS)* 15 (103), 5911-5916.

Reviews and Guidelines:

1. Belavgeni A., Meyer C., Stumpf J., Hugo C. and Linkermann A. (2020) Ferroptosis and Necroptosis in the Kidney. *Cell Chemical Biology* - Apr 16;27(4):448-462
2. Del Re, D., Amgalan, D., **Linkermann, A.**, Liu, Q and Kitsis, R.N. (2019) Fundamental Mechanisms of Regulated Cell Death and Implications for Heart Disease. *Physiological Reviews* Oct 1;99(4):1765-1817
3. Tonnus W., Gembardt F., Latk M., Parmentier S., Hugo S., Bornstein S.R. and **Linkermann A.** (2019) The Clinical Relevance of Necroinflammation – Highlighting the Importance of Acute Kidney Injury and the Adrenal Glands. *Cell Death and Differentiation* Jan;26(1):68-82
4. Bornstein S.R., Steenblock C., Chrousos G.P., Schally A.V., Beuschlein F., Kline G., Krone N.P., Licinio J., Wong M.L., Ullmann E., Ruiz-Babot G., Boehm B.O., Behrens A., Brennand A., Santambrogio A., Berger I., Werdermann M., Sancho R., **Linkermann A.**, Lenders J.W., Eisenhofer G. and Andoniadou C.L. (2018) Stress-inducible Stem Cells: A new View on Endocrine, Metabolic and Mental Disease? *Molecular Psychiatry* Sep 21. doi: 10.1038/s41380-018-0244-9.
5. Sarhan, M., Land, W., Tonnus, W., Hugo, C. and **Linkermann, A.** (2018) Origin and Consequences of Necroinflammation. *Physiological Reviews* Apr 1;98(2):727-780.
6. Sarhan, M., von Mässenhausen, A., Hugo, C. and **Linkermann, A.** (2018) Immunological consequences of kidney cell death *Cell Death and Disease* – Jan 25;9(2):114.
7. Martin-Sanchez, D., Fontecha-Barriuso, M., Sanchez-Niño, M.D., Ramos, A.M., Cabello, R., Gonzalez-Enguita, C., **Linkermann, A.**, Sanz, A.B., Ortiz, A. (2018) Cell death-based approaches in treatment of the urinary tract-associated diseases: a fight for survival in the killing fields *Cell Death and Disease* – Jan 25;9(2):118
8. Galluzzi L., [...], **Linkermann A.** [...] and Kroemer G. (2018) Molecular mechanisms of cell death: recommendations of the Nomenclature Committee on Cell Death 2018. *Cell Death and Differentiation* - in press
9. Stockwell, B.R., {...} **Linkermann A.**, {...} (2017). Ferroptosis: a regulated cell death nexus linking metabolism, redox biology, and disease. *Cell* – Oct 5;171(2):273-285
10. Tonnus, W. and Linkermann, A. (2017) The *in vivo* relevance for regulated necrosis *Immunological Reviews* May;277(1):128-149
11. Land W.G., Agostinis P., Gasser, S., Garg, A.G. and **Linkermann, A.** (2016) DAMP – Induced Allograft and Tumor Rejection: the Circle is Closing. *American journal of Transplantation* – Dec;16(12):3322-3337
12. Land W.G., Agostinis P., Gasser, S., Garg, A.G. and **Linkermann, A.** (2016) Transplantation and Damage Associated Molecular Patterns (DAMPs). *American journal of Transplantation* – Dec; 16(12):3338-3361
13. **Linkermann A.** (2016). Non-apoptotic cell death in acute kidney injury and transplantation. *Kidney International* 89, 46–57
14. Degtarev A. and **Linkermann A.** (2016). Generation of small molecules to interfere with regulated necrosis. *Cellular and Molecular Life Sciences*. 73(11-12):2251-67.
15. Kers J., Leemans J.C. and **Linkermann A.** (2016) An overview on pathways of regulated necrosis in kidney cell death. *Seminars in Nephrology* 73(11-12):2123-4.
16. Klionsky, D.J. [...], **Linkermann A.**, [...](2016) Guidelines for the use and interpretation of assays for monitoring autophagy (2nd edition) *Autophagy* 2016 Jan 2;12(1):1-222.
17. Simeoni L., Thurm C. Kritikos A. and **Linkermann A.** (2016) Redox homeostasis, T cells and kidney disease: three faces in the dark. *Clinical Kidney Journal* Feb;9(1):1-10.
18. Zhao H, Jaffer T, Eguchi S, Wang Z, **Linkermann A**, Ma D. (2015) Role of necroptosis in the pathogenesis of solid organ injury. *Cell Death Dis*. Nov 19;6:e1975
19. Mulay, S.R., **Linkermann A.** and Anders H.J. (2015): Necroinflammation in kidney disease. *Journal of the American Society of Nephrology (JASN)* Jan;27(1):27-39

20. **Linkermann, A.**, Stockwell, B.R., Krautwald, S. and Anders, A. (2014). Regulated Cell Death and Inflammation – An Auto-amplification Loop causes Organ Failure. *Nature Reviews Immunology* 14(11):759-67
21. Galluzzi L., [...], **Linkermann A.** [...] and Kroemer G.: Recommendations of the nomenclature committee on cell death. *Cell Death and Differentiation* Jan;22(1):58-73.
22. **Linkermann, A.**, Chen G., Dong, G., Kunzendorf, U., Krautwald, S., Dong Z. (2014). Regulated Cell Death in Acute Kidney Injury. *Journal of the American Society of Nephrology (JASN)* 25(12):2689-701
23. **Linkermann, A.** and Green, D.R. (2014) Mechanisms of Disease: Necroptosis. *New England Journal of Medicine (NEJM)* (350, (5): 455-465)
24. Vanden Berghe, T.*, **Linkermann, A.***, Takahashi, N., Walczak, H., Vandenabeele P. (2014). Regulated Necrosis: an Expanding Wealth of Cell Death Pathways. *Nature Reviews - Molecular Cell Biology* (23, 15(2): 135-47) *shared first authorship
25. **Linkermann, A.**, Hackl, M., Kunzendorf, U., Walczak H., Krautwald, S. and Jevnikar A.M. (2013) Necroptosis in Immunity and Ischemia-Reperfusion Injury. *American Journal of Transplantation* (13(11):2797-804) – cover story
26. **Linkermann, A.** De Zen, F., Weinberg, J., Kunzendorf, U., Krautwald, S. (2012). Programmed Necrosis in Acute Kidney Injury. *Nephrology Dialysis Transplantation* (invited review) Sep;27(9):3412-9.
27. **Linkermann, A.**, Qian, J., Lettau, M., Kabelitz, D., Janssen O. (2005): Considering Fas Ligand as a target for therapy. *Expert Opinion on Therapeutic Targets* 9(1), 119-34
28. **Linkermann, A.**, Qian, J., Kabelitz, D., Janssen, O. (2003): The Fas ligand as a cell death factor and signal transducer. *Signal Transduction*, 3, 9-47
29. **Linkermann, A.**, Qian, J., Janssen, O. (2003): Slowly getting a clue on CD95 ligand biology. *Biochemical Pharmacology*, 66, 1417-1426
30. Janssen, O., Qian, J., **Linkermann, A.**, Kabelitz, D. (2003): CD95L – death factor and costimulatory molecule? *Cell Death and Differentiation*, 10, 1215-1225

Editorials:

1. Schnieke A., Locke S. and Linkermann A. (2020) Precondition your donor pig for your successful allograft *American Journal of Transplantation - Epub ahead of print*
2. Belavgeni A., Bornstein S.R. and **Linkermann A.** (2019) Prominin-2 Suppresses Ferroptosis Sensitivity *Developmental Cell* Dec 2;51(5):548-549
3. Linkermann A and Kulms D (2019) Cell death and regeneration in Dresden-the 27th meeting of the European Cell Death Organization *Cell Death and Disease* Dec 4;10(12):910
4. Tonnus W and **Linkermann A.** (2019) Gasdermin D and Pyroptosis in AKI *Kidney International* Nov;96(5):1061-1063
5. Tonnus W, Belavgeni A, Xu Y, **Linkermann A.** (2019) Don't trick me twice *Kidney International* Apr;95(4):736-738
6. **Linkermann A.** (2019) Death and Fire *Cell Death and Differentiation* Jan;26(1):1-3
7. **Linkermann A.**, Parmentier, S., and Hugo C. (2018) We Aim2 inflame *JASN*, Apr;29(4):1077-1079
8. **Linkermann A.**, Stockwell B.R. and Vanden Berghe, T. (2017) Heavy Metal Suicide *AJP renal* – Oct 1;313(4):F959-F960
9. Tonnus W., Gemhardt F., Hugo C. and **Linkermann A.** (2017) Die later with ESCRT! *Oncotarget* – Jun 27;8(26):41790-41791
10. Todorov, V. and **Linkermann A.** (2017) Back to the Roots of Regulated Necrosis *Journal of Cell Science (JCS)* Feb;216(2):303-304
11. Tonnus, W., Hugo C. and **Linkermann A.** (2017) Gimme a Complex! Resident mononuclear phagocytes in the kidney as monitors of circulating antigens and immune complexes. *Kidney International* Feb;91(2):267-269
12. Schulte, K. and **Linkermann A.** (2016) Welcome to the Jungle – The Kidney during Sepsis. *American Journal of Respiratory and Critical Care Medicine (AJRCCM)* Sep 15;194(6):649-50

13. Tonnus, W. and **Linkermann A.** (2016) “Death is my Heir” – Ferroptosis Connects Cancer Pharmacogenomics and Ischemia-Reperfusion Injury. *Cell Chemical Biology* Vol. 23, Issue 2, p225–235.
14. **Linkermann A.**, Konstantinidis K, Kitsis RN. (2015) Catch me if you can: targeting the mitochondrial permeability transition pore in myocardial infarction. *Cell Death Differ.* 2016 Jan;23(1):1-2
15. Vanden Berghe, T. and **Linkermann, A.** (2014). Take my breath away: Necrosis in kidney transplants kills the lungs! *Kidney International* Apr;87(4):680-2.
16. **Linkermann A.**, Kunzendorf, U. and Krautwald S (2014). Phosphorylated MLKL causes plasma membrane rupture. *Molecular and Cellular Oncology* Aug 13;1(1):e29915
17. Krautwald S. and **Linkermann A.** (2014). The fire within – pyroptosis in the kidney. *AJP renal*, 306(2):F168-9

Clinical Case Reports:

1. Foltys D., **Linkermann A.**, Heumann A., Hoppe-Lotichius M., Heise M., Schad A., Schneider J., Bender K., Schmid M., Mauer D., Peixoto N., Otto G. Organ recipients suffering from undifferentiated neuroendocrine small-cell carcinoma of donor origin: a case report. *Transplant Proc.* 2009 Jul-Aug;41(6):2639-42.

Meeting Reports:

1. **Linkermann A.** and Kulms D. (2019) Cell death and regeneration in Dresden-the 27th meeting of the European Cell Death Organization. *Cell Death and Disease* 2019 Dec 4;10(12):910.

Books:

1. Tonnus W., Belavgeni A. and **Linkermann A.** Regulated Necrosis and Its Immunogenicity (2021). *Clinical Immunology* – in press
2. Tonnus W. and **Linkermann A.** Regulated Necrosis and Its Immunogenicity (2018). *Clinical Immunology* ISBN: 978-0-7020-6896-6; PII: B978-0-7020-6896-6.00013-2
3. Tonnus W, Al-Mekhlafi M, Hugo C, **Linkermann A.** (2018) Assessment of *In Vivo* Kidney Cell Death: Acute Kidney Injury *Methods Mol Biol.* 1857:135-144. doi: 10.1007/978-1-4939-8754-2_13.
4. Tonnus W, Al-Mekhlafi M, Gembardt F., Hugo C, **Linkermann A.** (2018) Assessment of *In Vivo* Kidney Cell Death: Glomerular Injury *Methods Mol Biol.* 1857:145-151. doi: 10.1007/978-1-4939-8754-2_14.
5. **Linkermann, A.** Necrotic cell death in ischemia reperfusion injury (2014). *Necrotic Cell Death.* Springer/Humana Press (Vol. 2). Zheng Dong and Peter Vandenabeele (Ed.), ISBN 978-1-4614-8220-8
6. Kunzendorf, U., **Linkermann, A.**, Rölver L., Heemann, U. (2010): Tacrolimus: Evidenz und Erfahrung. *Kardiovaskulärer Schutz nach Transplantation*, Band 3, 1-16. Pernmanyer, 2010, ISBN 8499261612
7. **Linkermann, A.**, Qian, J., Janssen, O., Chapter 7, Retrograde Fas Ligand signalling (2006). *Fas signaling.* Landes Bioscience, Wajant H (Ed.), VIII, Hardcover, ISBN: 978-0-387-32172-1

Clinical Reviews in German Journals:

1. **Linkermann A.** (2015): Bedeutung regulierter Zelltodprogramme für die Transplantation solider Organe. *Der Nephrologe*, 2015/2: 100-106.
2. **Linkermann A.** (2014): Regulated necrosis – A pathophysiological principle of acute kidney injury. *Dialyse aktuell*, 18(8): 430-433
3. Feldkamp, T, **Linkermann, A.** (2013): Immunsuppressive Therapie nach Nierentransplantation - Vermeidung von Steroiden und Calcineurin-Inhibitoren. *Der Nephrologe*, 3:220-225.
4. Kunzendorf, U., **Linkermann, A.** (2011): Renal Transplantation – Specific aspects regarding elder dialysis patients. *Dialyse aktuell*, 15(10): 568-575

5. **Linkermann, A.**, Kunzendorf, U. (2010): Orale Tolvaptan-Therapie: Ist diese sicher und effektiv zur Behandlung der chronischen Hyponatriämie?. *Der Nephrologe*, 5:239–241
6. **Linkermann, A.**, Kunzendorf, U. (2007): Tolvaptan ist ein selektiver oraler Vasopressin-V2-Rezeptor-Antagonist für die Therapie der Hyponatriämie. *Der Nephrologe*, 2:121–123

Patents:

1. **06/2016:** Sorafenib tosylate as necroptosis inhibitor (Patent number 11726338001, Patent application number GB1609641.4).
2. **08/2019:** Nec-1f – an inhibitor of both necroptosis and ferroptosis (patent signed).

Selected invited lectures and session chairs

This list excludes > 30 national and international seminar invitations, amongst which are invited seminars to the Ce-M-M, Vienna (**G. Superti-Furga**), Université Rene Descartes, Paris (**G. Kroemer**), Hospital Tenon, Paris (**P. Ronco**), UCL-Cancer Institute (**H. Walczak**), NIBS, Beijing (**X. Wang**), Columbia University, NYC (**B. Stockwell**), Mount Sinai Medical Center, NYC (**I. Daehn**), MSKCC, NYC (**S. Lowe**), Albert Einstein College of Medicine, NYC (**R. Kitis**), HMS, Boston (**J. Yuan**), HMS, Boston (**Joseph V. Bonventre**), Boston University (**S. Borkan**), Yale University, New Haven (**L. Cantley**), Emory University, Atlanta (**E. Mockarski**), Genentech, San Francisco (**V. Dixit**), Imperial College London (**D. Ma**), VIB Ghent (**P. Vandenabeele**), Semmelweis-University, Budapest (**A. Szabo**), University of Magdeburg (**B. Schraven**), Soochow University, Suzhou (**S. He**), Shanghai University, Shanghai (**L. Sun**), University of Madrid, Madrid (**A. Ortiz**), University of Alabama, Birmingham (**A. Agarwal**), St. Jude Medical Center – Department of Immunology (**D. Green**), Columbia University, NYC (**J. Barasch** and **Q. Al-Awqati**), Starzl Center for Transplantation, Pittsburgh, PA (**V. Kagan** and **F. Lakis**).

1. “Fas Ligand mediates fratricide in renal proximal tubular cells *in vivo*.” **19. Jahrestagung der Deutschen Transplantationsgesellschaft 2010**, (*selected abstract*)
2. „RIP1-Mediated Necroptosis Essentially Contributes to Renal Ischemia/Reperfusion Injury.” **20. Jahrestagung der Deutschen Transplantationsgesellschaft 2011**, (*selected abstract*)
3. „Loss of Acid Sphingomyelinase Causes Defective Autophagy-*induction in vivo* and Sensitizes for Renal Ischemia/Reperfusion Injury.” **ASN 2012 – San Diego, CA**, Session on Acute kidney injury I. (*selected abstract*)
4. “Identification of two Independent Pathways that Regulate Necrosis *in vivo*.” **CSH Asia Non-apoptotic cell death 2013**, Shanghai, China. (*selected abstract*)
5. “Two different pathways of regulated necrosis mediate ischemia-reperfusion injury.” **ECDO-annual meeting 2013**, Paris. Session on “Emerging cell death pathways” (*selected abstract*)
6. “Programmed Necrosis in AKI.” **ASN 2013 – Atlanta, GA**, Session “Dying to know: New Cell Death Pathways in AKI” (*invited speaker*).
7. “Regulated Necrosis in Ischemia-Reperfusion Injury.” **AACR 2014 – San Diego, CA.**, Major Symposium on “Novel pathways of non-apoptotic cell death” (*invited speaker*).
8. “The relative contribution of pathways of regulated necrosis to ischemic overall organ damage.” **Gordon Research Conference on Cell Death**, Mount Snow 06/14 (*invited speaker*).

9. “Necroptosis in Solid Organ Transplantation.” **World Transplant Congress – Sunrise Symposium (WTC2014)**, San Francisco 08/14 (*invited speaker*).
10. “Regulated Necrosis.” 19th Joint Meeting of the Signal Transduction Society, Weimar (*invited honorary lecture associated with the STS science Award*).
11. “The Necro-inflammatory auto-amplification loop of regulated necrosis and inflammation.” **Immunotherapy 2014**, La Havana, Cuba (*invited speaker*)
12. “50 ways or more to die.” **Joint British Transplantation Society and Nederlandse Transplantatie Vereniging Congress 2015 – Major Symposium**, Bournemouth, UK (*invited speaker*).
13. “Ferroptosis in Acute Kidney Injury.” **World Congress of Nephrology 2015** (ISN Annual Meeting 2015) (*selected abstract*)
14. “Beyond apoptosis and necroptosis: synchronized necrosis of renal tubules.” **International Symposium 2015 on Kidney Fibrogenesis**. Montabaur, Germany (*invited speaker*).
15. “Regulated Necrosis in Acute Kidney Injury.” **5th International Symposium on Molecular Targets in Renal Disease** (Bamberg, Germany). (*invited speaker*)
16. “Regulated Necrosis: Ferroptosis and permeability transition.” **Federation of European Physiological Societies (FEPS) meeting 2015 – major symposium**, Kaunas, Lithuania (*invited speaker*).
17. **Cold Spring Harbor Meeting “Cell Death” 2015** – (*invited speaker – discussion leader*).
18. “Trapped in the Iron Maiden – How kidneys die by ferroptosis!” **ECDO-annual meeting 2015**, Geneva (*invited speaker*)
19. **German Society of Nephrology (DGfN) annual meeting 2015** (Berlin, Germany). (*invited speaker*)
20. **German Society of Transplantation – annual meeting 2015** (Dresden, Germany). (*invited speaker*)
21. “Necroptosis and inflammation in AKI” **ASN 2015 – San Diego, CA**, Session on “Dead but not gone: cell death at the beginning of health and disease” (*invited speaker*)
22. **Cold Spring Harbor Asia Meeting “Targeting Cell Death Mechanisms for the Treatment of Human Diseases”**, Suzhou, China 2015 – (*invited speaker*).
23. **ERA-EDTA Annual Conference 2016, “Novel concepts on Transplant Rejection”**, Vienna, Austria, 2016 – (*invited speaker*).
24. **American Transplant Congress “Necroptosis in Transplantation”**, Boston, USA 2016 – (*invited speaker*)
25. “Phenytoin inhibits necroptosis *in vitro* and *in vivo*.” **Gordon Research Conference on Cell Death**, Barcelona 06/16 (*invited speaker*).
26. “Regulated Cell Death Pathways and Allograft Rejection” **26th International Congress of The Transplantation Society**, Hong Kong, 08/2016 (*invited speaker and discussion leader*).
27. “Cellular Response to Signaling and Oxidative Stress: Suicide or Survival” **ASN 2016 – Chicago (discussion leader)**
28. “The Future of Clinical Trials for the Prevention of Regulated Necrosis.” **DEATH in the ALPS: Cell Death, Inflammation and Cancer (invited speaker)**
29. pMLKL detection in human kidney transplant biopsies – 2017 Fusion conference on Cell death and Inflammation (*invited speaker*)
30. Cold Spring Harbor - **Banbury-Symposium** – The *in vivo* relevance of ferroptosis (*invited speaker and discussion leader*)
31. Potential clinical trials for the prevention of Regulated Necrosis: Rockville NIH **Symposium / Transplant panel (invited speaker)** π

32. Small molecules for the interference with Necroptosis and Ferroptosis - **ACS 2017, Philadelphia (invited speaker)**
33. Necroptosis in health and disease - **10th Tuscany Retreat on Cancer Research and Apoptosis – (Opening Plenary Lecture)**
34. NETs, Necroptosis and ANCA vasculitis **ECDO Conference on Cell Death, Leuven, Belgium (selected abstract).**
35. Regulated Necrosis as a therapeutic target - **SFB/TRR 127-autumn workshop – Venice, Italy (keynote lecture)**
36. Ferroptosis as a target in Transplantation – **German Transplant Society Meeting 2017 (invited speaker)**
37. Necroptosis and Ferroptosis in Acute Kidney Injury – **ASN 2017 – New Orleans (invited speaker)**
38. Necroinflammation as a Driver and Novel Therapeutic Target of Autoimmunity. **2018 AKI/CRRT conference – San Diego, USA (invited speaker)**
39. Necroptosis and Ferroptosis as druggable targets – **FiMC 2018 Frontiers in Medicinal Chemistry – Jena, Germany (keynote lecture)**
40. Regulated Necrosis in Acute Kidney Injury – **German Society of Pathology meeting 2018 – Berlin (keynote speaker)**
41. Necroinflammation as a cause of kidney transplant rejection – **World Transplant Conference (TTS) 2018 – Madrid, Spain (invited speaker)**
42. Necroinflammation – **Montmartre Immunology Meeting 2018 – Paris, France (invited speaker)**
43. Necroinflammation as a driver of acute rejection – **American Transplant Congress 2018, Seattle (invited speaker)**
44. Regulated cell death pathways in transplantation - **American Transplant Congress 2018, Seattle (invited speaker)**
45. Ferroptosis as a novel target in Solid Organ Injury – **EMBO Workshop on Phagocytosis 2018 – Gent (invited speaker)**
46. New Kids on the Block: CD4+ T-Cell Populations in Autoimmune Kidney Diseases – **ASN 2018 (discussion leader)**
47. Ferroptosis, Necroptosis and other pathways of regulated necrosis in AKI. – Session on “A Million Ways to Die in the Kidney” **ASN 2018 (invited speaker)**
48. Necroinflammation as a Driver of Transplant Rejection – **27. Jahrestagung der Deutschen Transplantationsgesellschaft (Master Class) – Berlin (invited speaker)**
49. Immunological consequences of ferroptotic cell death – **Cold Spring Harbor Asia Meeting on Iron Dependent Cell Death 2018 – Suzhou, China (invited speaker)**
50. The Origin of Donor Specific Antibodies – **ISN Meeting 2019, Melbourne, Australia (invited speaker and discussion leader)**
51. Necrosis in Ischemia and Acute Organ Injury – **2nd Fusion Conference on Cell Death, Puerto Vallarta, Mexico (invited speaker)**
52. Origin and Consequences of Necroinflammation - **16th Annual International Innate Immunity Conference, Aegan Conferences, Rhodos, Greece (invited speaker)**
53. Confused by the killers? Necroptosis, Pyroptosis and Ferroptosis in Acute Organ Injury – **EKFS-Symposium Würzburg, Germany (invited speaker)**
54. The role of Gasdermin D in diverse disease models (CSH meeting – Cell Death 2019) – **Cold Spring Harbor, NY, USA (invited speaker)**
55. Acute kidney injury - regulated cell death (necroptosis - ferroptosis), **31st European Congress of Pathology, Nice, France (invited speaker)**

56. Ischemia and reperfusion injury in kidney transplantation (ESOT 2019), Copenhagen, Denmark (*invited speaker* and *discussion leader*)
57. 27th Euroconference on Apoptosis (ECDO 2019) – Dresden, Germany (***Chair of Organizing Committee***) – www.ecdo.eu/ecdo2019
58. Regulierte Nekrose in der Transplantationsmedizin – Jahrestagung der Deutschen Gesellschaft für Transplantationsmedizin (DTG 2019), Hannover, Germany (*invited speaker* and *session chair*)
59. Confused by the Killers? Necroptosis, Pyroptosis and Ferroptosis in Acute Kidney Injury and Transplantation, Jahrestagung 2019 Österreichische Gesellschaft für Allergologie und Immunologie (ÖGAI), Graz, Austria (*keynote speaker*)
60. Pathophysiology of Acute Kidney Injury – Austrian-Czech-Annual Meeting on Nephrology, Prague, Czech Republic (*invited speaker*)
61. Cell Death Propagation during Ferroptosis – FOR2036 symposium (SFB/TRR on BCL2) – Obergurgl, Austria (*invited speaker*)

upcoming conferences with confirmed participation:

62. Regulated Necrosis induced by nucleotide sensing – TRR 237 international meeting 2020 on “Defects of the innate immune system in autoinflammation and autoimmunity”, Dresden, Germany (*invited speaker*)
63. “Ferroptosis” – 2020 Canadian Transplant Summit – Manitoba, Canada (*invited speaker*)
64. The role of ferroptosis as a driver of kidney transplant rejection – 2020 Central European Meeting of Nephrology, Vienna, Austria (*invited speaker*)
65. IUPS 2021 – (Title to be announced) – Beijing, China (*invited speaker*)

Editorial activities

| | |
|--|-----------------------------|
| Cell Death and Disease (NPG): | Senior Editor |
| Journal of the American Society of Nephrology (JASN) | Editorial Board Member |
| American Journal of Transplantation (AJT) | Editorial Board Member |
| Molecular and Cellular Oncology: | Editorial Board Member |
| American Journal of Physiology – Renal Physiology: | Editorial Board Member |
| Kidney360 (ASN) | Editorial Board Member |
| Clinical Kidney Journal (former NDT Plus): | Senior Editor/Basic Science |
| Cell Death and Differentiation (NPG): | Guest Editor 2018 |
| Cellular and Molecular Life Sciences: | Guest Editor 2016 |
| Seminars in Nephrology: | Guest Editor 2015 |

Third party funding:

| | | | |
|-----------------------------------|-------------|---|---------------------------|
| 1. | 2008 - 2009 | Else-Kröner-Fresenius-Stiftung | 50.000 € |
| | | „Einfluss der Blockade des Zelltod-vermittelnden Komplexes aus Fas und Fas Ligand auf das akute Nierenversagen“ | |
| 2. | 2009 - 2010 | Intramurale Förderung der UK-SH | 30.000 € |
| | | „Apoptoseblockade im akuten Kontrastmittel-induzierten Nierenversagen“ | |
| 3. | 2010 - 2011 | Hans-Werner Jackstädt Stiftung | 46.000 € |
| | | „Pharmakodynamik und Pharmakokinetik von TAT-crmA im Mausmodell des akuten Nierenversagens“ | |
| 4. | 2010 - 2011 | Intramurale Förderung des UK-SH | 20.000 € |
| | | „Apoptoseblockade im akuten Kontrastmittel-induzierten Nierenversagen“ | |
| 5. | 2011 - 2012 | DGfN Forschungsstipendium | 25.000 € |
| | | „Analyse der Immunzell-unabhängigen Nekroptose nach Renaler Ischämie/Reperfusion“ | |
| 6. | 2012 - 2013 | Projektförderung der Firma Novartis | 47.100 € |
| | | „Untersuchungen zu molekularen Mechanismen des programmierten Zelltods und Interventionsoptionen mittels TAT-RHIM“ | |
| 7. | 2013 | Projektförderung der Firma Novartis | 41.650 € |
| | | „Untersuchungen zum programmierten Zelltod und Interventionsoptionen mittels TAT-RHIM in vivo“ | |
| 8. | 2013 | Pfizer International Grant | 39.900 € |
| | | „Crosstalk between Rapamycin-induced Autophagy and Regulated Necrosis in Kidney Ischemia-Reperfusion Injury“ | |
| 9. | 2013 - 2015 | Projektförderung der Firma Fresenius | 120.000 € |
| | | „Transplantation von Nekroptose-insensitiven Inselzellen zur Behandlung des Streptozozin-induzierten Diabetes Mellitus“ | |
| 10. | 2013 - 2015 | Hans-Werner Jackstädt Stiftung | 40.000 € |
| | | „Mechanismen der Regulierten Nekrose im Akuten Nierenversagen“ | |
| 11. | 2014 - 2017 | German Research Foundation (EXC306) | 658.138€ |
| | | „Control of inflammation by regulated necrosis from Hydra to man“ | |
| 13. | 2018 - 2021 | Clinician Scientist – SFB/TRR205 | 456.000€ |
| | | “The Adrenal – Central Relay in Health and Disease” | |
| 12. | 2019 - 2023 | German Research Foundation (DFG) – Heisenberg Professorship | 700.000€ |
| | | „Heisenberg-Professorship for Clinical Cell Death Research“ | |
| 14. | 2019 | ECDO 2019 – SFB (30.500€) and TU Dresden (19.500€) | 50.000€ |
| | | International conference support | |
| 15. | 2020 | IRTG 2251 | 205.200€ |
| | | “The role of zinc in ferroptosis” | |
| 16. | 2020 | Else Kröner-Fresenius Stiftung - Translatorik | 698.076€ |
| | | “The Role of Necroinflammation in Preclinical Porcine-to-non-Human Primate Kidney Xenotransplantation” | |
| 17. | 2020 | Wilhelm Sander-Stiftung | 183.930€ |
| | | “Die Rolle der Regulierten Nekrose bei Adrenokortikalen Karzinomen und ihr therapeutisches Potential” | |
| Total third-party funding: | | | <u>3.410.994 €</u> |